- Institution: Stanford Univ Med Ctr Lane Med Lib/Periodical Dept/Rm L109
- Sign In as Member / Individual
Antiangiogenic Drugs: Insights into Drug Development from Endostatin, Avastin and Thalidomide
Table 3
VEGF Pathway Targets: Approaches for Drug Design
| Target | Approach |
|---|---|
| VEGF | Antibody (e.g., Avastin); soluble VEGF receptor (e.g., VEGF trap, aflibercept) |
| VEGF receptor (extracellular) | Antibody (e.g., DC101) |
| VEGF receptor phosphorylation | Tyrosine kinase inhibitors (e.g., Sorafenib, Sunitinib, vatalanib) |
| mRNA that encodes VEGF or receptor | Ribozyme (e.g., Angiozyme); siRNA technologies |
| Hypoxia-inducible factor | mTOR inhibitors (e.g., ridaforolimus) |
